2026-04-14
Pressmeddelande
The completed pilot phase in specialized treatment centers demonstrates significant potential for clinical practice, with results showing improved clarity, enhanced patient safety, and more efficient clinical workflows through a specialized library of medically validated phrases in numerous languages.
Clear and understandable communication is a cornerstone of safe care for people living with hemophilia. To specifically address language barriers, Bayer Vital GmbH and the Swedish health-tech company Care to Translate entered into a partnership in 2024. As part of this collaboration, a specialized medical language library for hemophilia care was developed and integrated into the Care to Translate app. Following a pilot phase across several specialized treatment centers, the solution aims to make medical consultations safer across language borders and provide patients with better access to vital health information.
Hemophilia requires precise education regarding therapy, medication use, and managing bleeding complications. Language barriers can pose a significant risk to both patients and healthcare professionals. The solution integrated into the Care to Translate app allows medical staff to quickly and reliably translate medically validated standard phrases into numerous languages. This enables structured patient consultations even when on-site interpreters are not immediately available.
The solution was tested at several specialized centers to evaluate its practical utility, including University Hospital Bonn, Saarland University Hospital, and Charité – Universitätsmedizin Berlin. The pilot phase demonstrated that digital language tools can significantly ease daily clinical communication, particularly during patient intake, when explaining therapy protocols, and when conveying critical safety information.
Dr. Georg Goldmann, Specialist in Transfusion Medicine and Hemostaseology at University Hospital Bonn, sees great potential:
"Especially with complex conditions like hemophilia, it is crucial that patients correctly understand therapy instructions. A digital solution with medically validated translations helps convey vital information quickly and clearly, thereby increasing patient safety."
At Saarland University Hospital, the practical benefits were equally clear. Prof. Dr. Hermann Eichler, Director of the Institute for Clinical Hemostaseology and Transfusion Medicine, emphasized the advantage of immediate availability:
"In daily clinical practice, situations often arise where we need to communicate with patients on short notice – whether during intake, for organizational questions, or explaining treatment steps. Having an app with verified medical translations available instantly is a major support."
Sara Giolo, Pediatric Nurse and Nursing Educator at Charité – Universitätsmedizin Berlin, highlighted the impact on the patient experience:
"When children and their families receive medical information in their own language, they feel safer and better understood. This strengthens the bond of trust and supports the entire treatment process."
The pilot phase also indicated that the benefits of such solutions extend far beyond hemophilia. Participating teams identified potential across various clinical areas, including emergency care, outpatient treatment, nursing, and general patient education. In an increasingly international healthcare system, digital language solutions can systematically reduce communication barriers and improve the overall quality of care.
The project evaluation underscores the power of collaboration between healthcare stakeholders. The goal is to make medical information accessible and improve communication between professionals and patients.
"The cooperation between the pilot centers, Bayer, and Care to Translate is an exemplary model for healthcare partnerships. Our joint commitment is to provide clear medical information and promote patient-centered solutions," says Christian Lauterbach, Managing Director of Bayer Vital GmbH.
Maja Magnusson, CEO of Care to Translate, added:
"This cooperation shows how healthcare partnerships can enable concrete improvements in everyday clinical life. Understandable communication is a core requirement for safe care. With medically validated real-time translations, we support medical staff in conveying important information quickly and reliably, even without immediate access to interpreter services."
Care to Translate is a digital communication tool developed specifically for the healthcare sector. It enables verified translation via text and voice in over 130 languages. The application is based on a curated library of medically validated phrases and is supported by AI technology. No patient data is stored, eliminating the risk of data compromise. It is used by over 800 healthcare organizations worldwide.
Bayer is committed to the hemophilia community. For over 30 years, they have worked alongside patients to understand their needs and hopes. Factor VIII replacement therapies remain the standard of care for managing bleeding. Bayer’s portfolio offers tailored treatments for people with Hemophilia A across all life stages and lifestyles.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission “Health for all, Hunger for none,” the company’s products and services are designed to benefit people and the planet. For more information, go to www.bayer.com.